VYNE Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- VYNE Therapeutics's estimated annual revenue is currently $26.5M per year.
- VYNE Therapeutics's estimated revenue per employee is $201,000
Employee Data
- VYNE Therapeutics has 132 Employees.
- VYNE Therapeutics grew their employee count by -50% last year.
VYNE Therapeutics's People
| Name | Title | Email/Phone |
|---|
VYNE Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is VYNE Therapeutics?
VYNE Therapeutics' mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
keywords:N/A
N/A
Total Funding
132
Number of Employees
$26.5M
Revenue (est)
-50%
Employee Growth %
N/A
Valuation
N/A
Accelerator
VYNE Therapeutics News
VYNE Therapeutics reported sales of $4.12 million in the same quarter last year, which indicates a negative year-over-year growth rate of 86.7%.
VYNE Therapeutics reported sales of $4.12 million in the same quarter last year, which indicates a negative year-over-year growth rate of 86.7%.
VYNE Therapeutics posted earnings per share of ($0.37) during the same quarter last year, which would suggest a positive year-over-year growth...
VYNE Therapeutics posted earnings per share of ($0.37) during the same quarter last year, which would suggest a positive year-over-year growth...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35.6M | 132 | 19% | N/A |
#2 | $18.5M | 132 | 28% | N/A |
#3 | $42.4M | 132 | 9% | N/A |
#4 | $32.3M | 132 | 10% | N/A |
#5 | $23.8M | 132 | 6% | N/A |